Table 2. Comparison of Prespecified and Stepwise Multivariable Logistic Regression Models for the Association of Pretreatment Variables and Treatment-Related or Posttreatment Variables With the Outcome of mRS Score of 2 or Less Despite Large FIV Among 1091 Patients in the Safety and Efficacy of Nerinetide in Subjects Undergoing Endovascular Thrombectomy for Stroke Trial .
| Variable | Outcome: FIV ≥92 mL with mRS score ≤2 | |||
|---|---|---|---|---|
| Model with pre-specified variables based on ESCAPE analysisa | Model with variables selected by stepwise multivariable logistic regressiona | |||
| aOR(95%CI) | P value | aOR(95%CI) | P value | |
| Pretreatment factors | ||||
| Age, per year | 0.97 (0.95-0.99) | .006 | 0.98 (0.96-0.99) | .02 |
| Vascular risk factors, No. | 0.99 (0.84-1.16) | .89 | NA | NA |
| Diabetes | NA | NA | 0.38 (0.16-0.92) | .03 |
| Baseline hemoglobin level, per g/L increase | NA | NA | 1.02 (1.00-1.03) | .04 |
| AUC (95% CI)b | 0.76 (0.70-0.82) | <.0001 | 0.77 (0.71-0.83) | <.0001 |
| Pearson χ2 | 703 | >.99 | 686 | >.99 |
| Hosmer-Lemeshow χ2 | 2.49 | .47 | 3.44 | .33 |
| Treatment-related and posttreatment factors | ||||
| Any SAE | 0.13 (0.05-0.30) | <.001 | NA | NA |
| Stroke progression | NA | NA | 0.05 (0.01-0.25) | <.001 |
| sICH | NA | NA | 0.15 (0.03-0.84) | .03 |
| DBP at 24 h, per mm Hg increase | NA | NA | 0.97 (0.94-0.99) | .003 |
| Glucose level at 24 h, per mmol/L increase | NA | NA | 0.82 (0.69-0.96) | .02 |
| Hemoglobin level at 24 h per g/L increase | NA | NA | 1.02 (1.01-1.04) | .009 |
| AUC (95% CI)c | 0.80 (0.74-0.87) | <.0001 | 0.79 (0.72-0.86) | <.0001 |
| Pearson χ2 | 830 | .34 | 725 | .93 |
| Hosmer-Lemeshow χ2 | 3.11 | .38 | 3.17 | .37 |
Abbreviations: aOR, adjusted odds ratio; AUC, area under the receiver operating characteristic curve; DBP, diastolic blood pressure; ESCAPE, Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to Recanalization Times; FIV, follow-up infarct volume; mRS, modified Rankin Scale; NA, not applicable; SAE, serious adverse event; sICH, symptomatic intracerebral hemorrhage.
a
All models were also adjusted for FIV, alteplase, nerinetide, and interaction of alteplase with nerinetide treatment.
b
No difference in AUC between pretreatment factor models 1 and 2 (P = .82).
c
No difference in AUC between posttreatment factor models 1 and 2 (P = .92).